Education
About Us
Working with TipRanks
Follow Us
Virpax Pharmaceuticals (VRPX)
NASDAQ:VRPX
RESEARCH TOOLSreports
VRPX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.17 - $4.83
Previous CloseN/A
Volume440.71K
Average Volume (3M)10.03M
Market Cap
$4.83M
Enterprise Value$3.22M
Total Cash (Recent Filing)$1.51M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.34
Next Earnings
Mar 26, 2025EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.15
Shares Outstanding26,562,580
10 Day Avg. Volume12,237,754
30 Day Avg. Volume10,025,497
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.40
P/FCF Ratio0.00
Enterprise Value/Market Cap0.67
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.27
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
---
Virpax Pharmaceuticals News
PremiumCompany Announcements
Virpax Pharmaceuticals Appoints Charn Deol as Independent Director
PremiumCompany Announcements
Virpax Pharmaceuticals Board Member Jay Panis Resigns
PremiumCompany Announcements
Virpax Pharmaceuticals Raises $6M and Signs Investor Agreements
PremiumCompany Announcements
Virpax Updates Executive Agreements for Legal Compliance
PremiumCompany Announcements
Virpax Pharmaceuticals Welcomes Jay Panis to Board---
Bulls Say, Bears Say
Bulls Say
Product DevelopmentProbudur found to successfully reduce pain in rat model, with positive study results consistent with prior studies.
Safety ProfileThe Molecular Envelope Technology (MET) study found no moderate-to-severe adverse events, indicating safety.
Bears Say
Financial PositionVirpax is capital constrained to file INDs and advance the products into clinical trials.
Leadership And ManagementVirpax's CEO and CFO both resigned, along with multiple board members, due to disagreements with execution of policies, practices, and procedures.
Stock PerformanceVirpax received a deficiency letter from Nasdaq since the stock was trading below <$1 for 30 consecutive business days and has until 4/2/25 to regain compliance.
---
Ownership Overview
0.12%
Insiders
0.26% Mutual Funds
0.13% Other Institutional Investors
99.58% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
VRPX FAQ
What was Virpax Pharmaceuticals’s price range in the past 12 months?
Virpax Pharmaceuticals lowest stock price was $0.17 and its highest was $4.83 in the past 12 months.
What is Virpax Pharmaceuticals’s market cap?
Virpax Pharmaceuticals’s market cap is $4.83M.
When is Virpax Pharmaceuticals’s upcoming earnings report date?
Virpax Pharmaceuticals’s upcoming earnings report date is Mar 26, 2025 which is in 13 days.
How were Virpax Pharmaceuticals’s earnings last quarter?
Virpax Pharmaceuticals released its earnings results on Nov 12, 2024. The company reported -$0.54 earnings per share for the quarter, the consensus estimate of -$0.54 by $0.
Is Virpax Pharmaceuticals overvalued?
According to Wall Street analysts Virpax Pharmaceuticals’s price is currently Overvalued.
Does Virpax Pharmaceuticals pay dividends?
Virpax Pharmaceuticals does not currently pay dividends.
What is Virpax Pharmaceuticals’s EPS estimate?
Virpax Pharmaceuticals’s EPS estimate is -0.37.
How many shares outstanding does Virpax Pharmaceuticals have?
Virpax Pharmaceuticals has 26,562,580 shares outstanding.
What happened to Virpax Pharmaceuticals’s price movement after its last earnings report?
Virpax Pharmaceuticals reported an EPS of -$0.54 in its last earnings report, expectations of -$0.54. Following the earnings report the stock price went down -6.061%.
Which hedge fund is a major shareholder of Virpax Pharmaceuticals?
Currently, no hedge funds are holding shares in VRPX
---
Company Description
Virpax Pharmaceuticals
Virpax Pharmaceuticals Inc is a preclinical-stage pharmaceutical company. The company is focused on developing pharmaceutical product candidates for pain management.
---
VRPX Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Aurinia Pharmaceuticals
―
ESSA Pharma
―
AnaptysBio
―
Kala Pharmaceuticals
―
Kezar Life Sciences
―
---